MXPA04002702A - Forma de dosificacion para el tratamiento de diabetes mellitus. - Google Patents

Forma de dosificacion para el tratamiento de diabetes mellitus.

Info

Publication number
MXPA04002702A
MXPA04002702A MXPA04002702A MXPA04002702A MXPA04002702A MX PA04002702 A MXPA04002702 A MX PA04002702A MX PA04002702 A MXPA04002702 A MX PA04002702A MX PA04002702 A MXPA04002702 A MX PA04002702A MX PA04002702 A MXPA04002702 A MX PA04002702A
Authority
MX
Mexico
Prior art keywords
treatment
dosage form
diabetes mellitus
biguanide
metformin
Prior art date
Application number
MXPA04002702A
Other languages
English (en)
Spanish (es)
Inventor
Z Tyebji Ziauddin
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MXPA04002702A publication Critical patent/MXPA04002702A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA04002702A 2001-09-28 2002-09-27 Forma de dosificacion para el tratamiento de diabetes mellitus. MXPA04002702A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN942MU2001 2001-09-28
IN941MU2001 2001-09-28
PCT/IN2002/000194 WO2003026637A2 (en) 2001-09-28 2002-09-27 Dosage form for treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
MXPA04002702A true MXPA04002702A (es) 2004-07-05

Family

ID=26324911

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002702A MXPA04002702A (es) 2001-09-28 2002-09-27 Forma de dosificacion para el tratamiento de diabetes mellitus.

Country Status (13)

Country Link
US (1) US20040202718A1 (enExample)
EP (1) EP1435931A2 (enExample)
JP (1) JP2005508331A (enExample)
KR (1) KR20040044992A (enExample)
CN (1) CN1635894A (enExample)
BR (1) BR0213079A (enExample)
CA (1) CA2461693A1 (enExample)
HU (1) HUP0402328A2 (enExample)
MX (1) MXPA04002702A (enExample)
PL (1) PL370818A1 (enExample)
RU (1) RU2004108219A (enExample)
WO (1) WO2003026637A2 (enExample)
ZA (1) ZA200402369B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003105809A1 (en) * 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US20060002998A1 (en) * 2002-11-15 2006-01-05 Anupam Trehan Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation
WO2004110422A1 (en) * 2003-06-16 2004-12-23 Ranbaxy Laboratories Limited Extended-release tablets of metformin
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
WO2005102290A1 (en) * 2004-04-22 2005-11-03 Ranbaxy Laboratories Limited Pharmaceutical compositions of a biguanide and a sulfonylurea
KR100705210B1 (ko) * 2004-09-23 2007-04-06 주식회사 한독약품 경구투여를 위한 당뇨병 치료용 약제학적 복합제제
WO2006038226A2 (en) * 2004-10-08 2006-04-13 Rubicon Research Pvt. Ltd. Process for making a highly compressible controlled delivery compositions of metformin
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
WO2006082523A2 (en) * 2005-01-25 2006-08-10 Aurobindo Pharma Limited Pharmaceutical sustained release composition of metformin
CA2607419C (en) * 2005-04-26 2014-06-17 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation containing biguanide compound
BRPI0608609A2 (pt) * 2005-05-10 2010-01-19 Novartis Ag processo de extrusço para preparaÇço de composiÇÕes com compostos terapÊuticos fracamente compressÍveis
WO2007072218A2 (en) * 2005-06-10 2007-06-28 Combino Pharm, S.L. Formulations containing glimepiride and/or its salts
KR100780553B1 (ko) * 2005-08-18 2007-11-29 한올제약주식회사 메트포르민 서방정 및 그의 제조방법
WO2007048223A2 (en) * 2005-10-25 2007-05-03 Pharmascience Inc. A gastric retention drug delivery system
RU2333760C2 (ru) * 2006-05-16 2008-09-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Твердая дозированная лекарственная форма для лечения сахарного диабета
UA98799C2 (ru) * 2007-07-19 2012-06-25 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
BRPI1007945C8 (pt) 2009-02-13 2021-05-25 Romark Laboratories Lc formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral
IT1401146B1 (it) * 2010-07-27 2013-07-12 Gnosis Spa Composizione comprendente shellac e/o un suo sale e sodio amido glicolato
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2013077825A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Preparation process for a formulation comprising metformin
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
WO2014141806A1 (ja) * 2013-03-11 2014-09-18 株式会社ニコン 電子機器及びプログラム
EP2783681A1 (en) * 2013-03-25 2014-10-01 Sanovel Ilac Sanayi ve Ticaret A.S. Extended release formulations of metformin
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN104906114A (zh) * 2015-06-18 2015-09-16 青岛海之星生物科技有限公司 一种二甲双胍格列喹酮复方缓释胶囊及制备方法
CN104906115A (zh) * 2015-06-18 2015-09-16 青岛海之星生物科技有限公司 一种二甲双胍格列喹酮复方缓释片及制备方法
CN106389446A (zh) * 2016-11-07 2017-02-15 华中药业股份有限公司 一种降糖药物组合物及其制备方法
CN107184559B (zh) * 2017-06-02 2018-07-31 广东赛康制药厂有限公司 一种盐酸二甲双胍缓释片及其制备方法
CN114404376A (zh) * 2022-03-16 2022-04-29 成都恒瑞制药有限公司 一种盐酸二甲双胍缓释片剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5576306A (en) * 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
PT1251832E (pt) * 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
DE10016356B4 (de) * 2000-04-03 2007-06-21 Beisel, Günther Mittel mit verbesserter Retardwirkung und Verfahren zu dessen Herstellung
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide

Also Published As

Publication number Publication date
HUP0402328A2 (hu) 2005-02-28
PL370818A1 (en) 2005-05-30
BR0213079A (pt) 2004-11-09
WO2003026637A2 (en) 2003-04-03
ZA200402369B (en) 2005-02-23
KR20040044992A (ko) 2004-05-31
JP2005508331A (ja) 2005-03-31
CN1635894A (zh) 2005-07-06
RU2004108219A (ru) 2005-03-10
WO2003026637A3 (en) 2003-05-01
CA2461693A1 (en) 2003-04-03
EP1435931A2 (en) 2004-07-14
US20040202718A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2003026637A3 (en) Dosage form for treatment of diabetes mellitus
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
PL355331A1 (en) Novel composition and use
EG24124A (en) Pharmaceutical compositions for the treatment of type-II diabetes mellitus
IL188471A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
LT2001092A (en) HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND USE THEREOF
WO1999040904A3 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia
AR010385A1 (es) Compuesto derivado de propiofenona, proceso para su preparacion, composicion farmaceutica que lo contiene y uso de dicho compuesto.
EP1545483A4 (en) NON-NUCLEOSIDIC INHIBITORS OF INVERSE TRANSCRIPTASES
WO2002060422A3 (en) Treatment of diabetes mellitus using vardenafil
AU1255002A (en) Delayed-release pharmaceutical formulations
IL153513A (en) Pharmaceutical preparation containing a combination of sulfonylurea as an antidiabetic agent and fbpase inhibitor and their use in the preparation of drugs for the treatment of diabetes
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
WO2002030467A3 (en) Pharmaceutical composition containing honey for the treatment of wounds
WO2002053090A3 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
IL167187A (en) Composition comprising modafinil, said composition for use as a medicament and use of said composition for the preparation of medicament
ZA200405342B (en) The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus
GB0212410D0 (en) Organic compounds
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
TW200510370A (en) Urea derivatives
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
AU2002257598A1 (en) Agent for treating diabetes mellitus
WO2004082582A3 (fr) Utilisation du diazoxide dans le traitement de l'ischemie retinienne
HUP0301915A3 (en) Use of sildenafil and other compounds with pde5 activity for the preparation of pharmaceutical composition treating premature ejaculation
PL357466A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them